Connect Biopharma Operating Margin vs. Debt To Equity
| CNTB Stock | USD 1.00 0.01 1.01% |
For Connect Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Connect Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Connect Biopharma Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Connect Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Connect Biopharma Holdings over time as well as its relative position and ranking within its peers.
Connect |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share 0.438 | Return On Assets (0.12) | Return On Equity (0.18) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Connect Biopharma Debt To Equity vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Connect Biopharma's current stock value. Our valuation model uses many indicators to compare Connect Biopharma value to that of its competitors to determine the firm's financial worth. Connect Biopharma Holdings is number one stock in operating margin category among its peers. It is rated below average in debt to equity category among its peers fabricating about 0.01 of Debt To Equity per Operating Margin. The ratio of Operating Margin to Debt To Equity for Connect Biopharma Holdings is roughly 123.20 . At present, Connect Biopharma's Operating Profit Margin is projected to stay steady based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Connect Biopharma's earnings, one of the primary drivers of an investment's value.Connect Debt To Equity vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Connect Biopharma |
| = | 0.25 % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Connect Biopharma |
| = | 0 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Connect Debt To Equity Comparison
Connect Biopharma is currently under evaluation in debt to equity category among its peers.
Connect Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Connect Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Connect Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Connect Biopharma's change in net profit over the period of time. It can combine multiple indicators of Connect Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 11.9 M | 12.4 M | |
| Net Loss | -1.2 B | -1.1 B | |
| Net Interest Income | 2.7 M | 2.8 M | |
| Interest Income | 2.7 M | 3.5 M | |
| Operating Income | -62.1 M | -65.2 M | |
| Net Loss | -59.5 M | -62.5 M | |
| Income Before Tax | -59.4 M | -62.4 M | |
| Total Other Income Expense Net | 2.7 M | 2.8 M | |
| Net Loss | -59.4 M | -62.4 M | |
| Income Tax Expense | 120 K | 126 K | |
| Change To Netincome | 847.5 M | 889.9 M | |
| Net Loss | (1.08) | (1.13) | |
| Income Quality | 0.81 | 0.46 | |
| Net Income Per E B T | 1.00 | 0.80 |
Connect Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Connect Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Connect Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Connect Biopharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Connect Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Use Investing Themes to Complement your Connect Biopharma position
In addition to having Connect Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Entertainment Thematic Idea Now
Entertainment
Companies from entertainment industry including show business, news and media. The Entertainment theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
To fully project Connect Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Connect Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Connect Biopharma's income statement, its balance sheet, and the statement of cash flows.